Deucravacitinib

Overview

Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 ( TYK2 ), with an IC 50 of 0.2 nM and a K i of 0.02 nM against the JH2 domain of TYK2 , and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23 , IL-12 , p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Skin Inflammation | Products > Disease Areas > Systemic Lupus Erythematosus | Products > Disease Areas > Psoriasis | Products > Disease Areas > Inflammatory Bowel Disease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > IFNAR | Products > Signaling Pathways > JAK | Products > Signaling Pathways > STAT | Products > Signaling Pathways > Interleukin Related

Product Information

• Catalog No.: HY-117287
• CAS No.: 1609392-27-9
• Molecular Formula: C20H19D3N8O3
• Molecular Weight: 425.46
• Purity: 99.93%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: 3.83 mg/mL (9.00 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source